11 evidence-first reviews in this topic, built on 55 peer-reviewed citations. Null and negative trials are reported alongside the positive ones — that is the point of the format.
Topical niacinamide at 4–5% over 8–12 weeks modestly improves fine lines, hyperpigmented spots, blotchiness, and barrier function in mostly split-face trials — real, gradual,…
Where the evidence lands: One of the better-evidenced cosmetic actives for modest, gradual improvement in photoaged skin; the striking skin-cancer numbers concern oral niacinamide in high-risk patients, not any serum.
Hyaluronic acid holds a thousand times its weight in water, declines with age, and has genuine randomized-trial support for skin hydration — topical and now oral. But wrinkle effects are…
Where the evidence lands: Topical hyaluronic acid reliably improves skin hydration and elasticity in controlled studies, with low-molecular-weight forms reducing wrinkle depth, and oral HA shows benefit over 8–12 weeks — but effects on wrinkles are modest, most trials are small and industry-linked, and the gains are largely hydration, not structural renewal.
Topical vitamin C has real, controlled-trial support for photoaged skin — fine lines, texture, pigmentation — but the trials are small, the formulations vary, the molecule is notoriously…
Where the evidence lands: Consistent use of a well-formulated vitamin C serum can measurably improve the appearance of photodamaged skin over weeks to months, but evidence is limited for L-ascorbic acid specifically, results depend on formulation stability, and this is dermatology, not longevity medicine.
Bakuchiol is marketed as retinol's gentler plant twin. A 12-week randomized trial backs the comparison — less scaling and stinging, comparable wrinkle results — but reviewers grade the…
Where the evidence lands: A 12-week randomized, double-blind trial found topical bakuchiol comparable to retinol for wrinkles and hyperpigmentation with less irritation, but the total evidence base is small, often unblinded, and high risk of bias — its best-established advantage is tolerability.
Copper tripeptide-1 stimulates collagen in the lab and connective tissue in rat wounds, and it has become a skincare-forum obsession. But the best controlled human test — a randomized…
Where the evidence lands: GHK-Cu has a strong mechanistic and animal case as a skin-remodeling signal, but rigorous human cosmetic evidence does not exist: no adequate placebo-controlled trials for photoaging or wrinkles, and the best controlled trial found no objective benefit over control — so treat it as a plausible supportive ingredient, not a proven anti-aging treatment.
Topical tranexamic acid significantly reduces melasma severity in randomized trials and meta-analyses, performing comparably to hydroquinone with fewer irritant effects — though trials are…
Where the evidence lands: For melasma and facial hyperpigmentation, topical tranexamic acid is one of the better-evidenced cosmeceuticals — effective at 2–5% concentrations over 8–12 weeks — but it manages a relapsing condition rather than curing it, and anti-aging claims are extrapolation.
Retinaldehyde is one enzymatic step from retinoic acid, the most proven molecule in topical anti-aging — and small randomized trials show it improves fine lines, texture, and hydration…
Where the evidence lands: Topical retinaldehyde at 0.05–0.1% has real randomized-trial support for improving photoaged skin's appearance with better tolerability than prescription retinoic acid — but the evidence base is small, short, and largely about how skin looks, not about aging itself.
Topical azelaic acid is one of the few skincare actives with high-certainty randomized-trial evidence — for papulopustular rosacea, at prescription strengths of 15–20%. What a roughly 10%…
Where the evidence lands: For inflammatory rosacea lesions and redness, azelaic acid has among the strongest evidence of any topical; expect one to two months before benefit, transient stinging as the common side effect, no effect on visible vessels, and weaker certainty at over-the-counter doses.
Alpha-lipoic acid is a potent, unusually versatile antioxidant, and one good split-face trial found a 5% cream measurably reduced facial roughness over 12 weeks. But controlled long-term…
Where the evidence lands: A randomized split-face trial showed 5% topical alpha-lipoic acid reduced skin roughness more than vehicle after 12 weeks (50.8% vs 40.7% on laser profilometry), supported by a smaller gel study — plausible, modest improvement in texture and fine lines, not systemic anti-aging, with long-term evidence still thin.
Human biopsy and controlled-trial evidence shows topical glycolic acid thickens epidermis, raises collagen and hyaluronic acid, and modestly improves photodamage and sallowness — while…
Where the evidence lands: Glycolic acid has real tissue-level evidence for texture, tone, and some photoaging markers; wrinkle benefits are modest and cumulative, and peel-strength products demand professional supervision.
In a randomized Australian trial, adults assigned to daily sunscreen showed no detectable increase in skin aging over 4.5 years and about 24% less photoaging than discretionary users;…
Where the evidence lands: Regular broad-spectrum sunscreen is one of the few anti-aging interventions with randomized-trial support — for photoaging and melanoma — though high-quality trials are few, certainty for keratinocyte cancers is lower than advertised, and sunscreen is no license for longer sun exposure.
55 distinct peer-reviewed papers, published 1993–2025, across 35 journals. Each links to its PubMed record; where Magellan has published a full study write-up, that is linked too.
Prefer the interactive version? Open the article feed in the Magellan app →